{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:28:05Z","timestamp":1761128885432},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.eururo.2011.04.024","type":"journal-article","created":{"date-parts":[[2011,4,22]],"date-time":"2011-04-22T05:48:37Z","timestamp":1303451317000},"page":"37-38","source":"Crossref","is-referenced-by-count":1,"title":["Thirty-Five Years of Intravesical Bacillus Calmette-Gu\u00e9rin for Bladder Cancer: Where Now?"],"prefix":"10.1016","volume":"60","author":[{"given":"James W.F.","family":"Catto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2011.04.024_bib0005","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2009.11.023","article-title":"The role of bacillus Calmette-Gu\u00e9rin in the treatment of non\u2013muscle-invasive bladder cancer","volume":"57","author":"Gontero","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.04.024_bib0060","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2011.03.051","article-title":"Bacillus Calmette-Gu\u00e9rin without maintenance therapy for high-risk non\u2013muscle-invasive bladder cancer","volume":"60","author":"Herr","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.04.024_bib0015","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Gu\u00e9rin for transitional-cell carcinoma of the bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2011.04.024_bib0020","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.04.024_bib0025","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.04.024_bib0055","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.04.024_bib0035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2009.08.024","article-title":"An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer","volume":"57","author":"Kulkarni","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.04.024_bib0040","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.04.024_bib0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.04.024_bib0050","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811004040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811004040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T07:53:35Z","timestamp":1543823615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283811004040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0302283811004040"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2011.04.024","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}